Aubie K. Shaw
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Aubie K. Shaw has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
Wade Bushman
8 shared publications- Bart O. Williams
Van Andel Institute
7 shared publications Bree D. Buckner-Berghuis
7 shared publicationsCassandra R. Zylstra
7 shared publicationsDaniel R. Robinson
7 shared publicationsHolli M. Charbonneau
7 shared publications
Latest Publications
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends 1-2 from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
Supplementary Figure Legends 1-2 from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends 1-2 from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
Supplementary Figure Legends 1-2 from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-2 from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
Supplementary Figures 1-2 from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-2 from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
Supplementary Figures 1-2 from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends 1-2 from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
Supplementary Figure Legends 1-2 from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends 1-2 from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
Supplementary Figure Legends 1-2 from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-2 from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
Supplementary Figures 1-2 from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-2 from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
Supplementary Figures 1-2 from Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
- Open Access
- 1 January 2019
- Published by Elsevier in Academic Pathology
- Vol. 6
Educational Case: Cytology for Staging Neoplasia and Thyroid Neoplasms
- 1 January 2019
- Published by Elsevier in Academic Pathology
- Vol. 6
Open AccessEducational Case: Cytology for Staging Neoplasia and Thyroid Neoplasms
- 1 February 2018
- Published by Elsevier in International Journal for Parasitology
- Vol. 48  (2) , 179-189
Tail characteristics of Trypanosoma brucei mitochondrial transcripts are developmentally altered in a transcript-specific manner
- 1 February 2018
- Published by Elsevier in International Journal for Parasitology
- Vol. 48  (2) , 179-189
Tail characteristics of Trypanosoma brucei mitochondrial transcripts are developmentally altered in a transcript-specific manner
- 29 July 2017
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 125
Surgical Procedures and Methodology for a Preclinical Murine Model of De Novo Mammary Cancer Metastasis
A rate-limiting aspect of transgenic mouse models of mammary adenocarcinoma is that primary tumor burden in mammary tissue typically defines study end-points. Thus, studies focused on elucidating mechanisms of late-stage de novo metastasis are compromised, as are studies examining efficacy of anti-cancer therapies targeting mediators of metastasis in the adjuvant setting. Numerous murine mammary cancer models have been developed via targeted expression of dominant oncoproteins to mammary epithelial cells yielding models variably mimicking histopathologic and transcriptome-defined breast cancer subtypes common in women1. While much has been learned regarding the biology of mammary carcinogenesis with these models, their utility in identifying molecules regulating growth of late-stage metastasis are compromised as mice are typically euthanized at earlier time points due to significant primary tumor burden. Moreover, since a significant percentage of women diagnosed with breast cancer receive adjuvant therapy after surgical resection of primary tumors and prior to presence of detectable metastatic disease, preclinical models of de novo metastasis are urgently needed as platforms to evaluate new therapies aimed at targeting metastatic foci. To address these deficiencies, we developed a murine model of de novo mammary cancer metastasis, wherein primary mammary tumors are surgically resected, and metastatic foci subsequently develop over a 115 day post-surgical period. This long latency provides a tractable model to identify functionally significant regulators of metastatic progression in mice lacking primary tumor, as well as a model to evaluate preclinical therapeutic efficacy of agents aimed at blocking functionally significant molecules aiding metastatic tumor survival and growth.
- 29 July 2017
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 125
Surgical Procedures and Methodology for a Preclinical Murine Model of De Novo Mammary Cancer Metastasis
A rate-limiting aspect of transgenic mouse models of mammary adenocarcinoma is that primary tumor burden in mammary tissue typically defines study end-points. Thus, studies focused on elucidating mechanisms of late-stage de novo metastasis are compromised, as are studies examining efficacy of anti-cancer therapies targeting mediators of metastasis in the adjuvant setting. Numerous murine mammary cancer models have been developed via targeted expression of dominant oncoproteins to mammary epithelial cells yielding models variably mimicking histopathologic and transcriptome-defined breast cancer subtypes common in women1. While much has been learned regarding the biology of mammary carcinogenesis with these models, their utility in identifying molecules regulating growth of late-stage metastasis are compromised as mice are typically euthanized at earlier time points due to significant primary tumor burden. Moreover, since a significant percentage of women diagnosed with breast cancer receive adjuvant therapy after surgical resection of primary tumors and prior to presence of detectable metastatic disease, preclinical models of de novo metastasis are urgently needed as platforms to evaluate new therapies aimed at targeting metastatic foci. To address these deficiencies, we developed a murine model of de novo mammary cancer metastasis, wherein primary mammary tumors are surgically resected, and metastatic foci subsequently develop over a 115 day post-surgical period. This long latency provides a tractable model to identify functionally significant regulators of metastatic progression in mice lacking primary tumor, as well as a model to evaluate preclinical therapeutic efficacy of agents aimed at blocking functionally significant molecules aiding metastatic tumor survival and growth.
- Top Cited Papers
- 26 September 2016
- Published by Springer Nature in Nature Nanotechnology
- Vol. 11  (11) , 986-994
Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues
Until now, the Food and Drug Administration (FDA)-approved iron supplement ferumoxytol and other iron oxide nanoparticles have been used for treating iron deficiency, as contrast agents for magnetic resonance imaging and as drug carriers. Here, we show an intrinsic therapeutic effect of ferumoxytol on the growth of early mammary cancers, and lung cancer metastases in liver and lungs. In vitro, adenocarcinoma cells co-incubated with ferumoxytol and macrophages showed increased caspase-3 activity. Macrophages exposed to ferumoxytol displayed increased mRNA associated with pro-inflammatory Th1-type responses. In vivo, ferumoxytol significantly inhibited growth of subcutaneous adenocarcinomas in mice. In addition, intravenous ferumoxytol treatment before intravenous tumour cell challenge prevented development of liver metastasis. Fluorescence-activated cell sorting (FACS) and histopathology studies showed that the observed tumour growth inhibition was accompanied by increased presence of pro-inflammatory M1 macrophages in the tumour tissues. Our results suggest that ferumoxytol could be applied ‘off label’ to protect the liver from metastatic seeds and potentiate macrophage-modulating cancer immunotherapies.
- 26 September 2016
- Published by Springer Nature in Nature Nanotechnology
- Vol. 11  (11) , 986-994
Top Cited PapersIron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues
Until now, the Food and Drug Administration (FDA)-approved iron supplement ferumoxytol and other iron oxide nanoparticles have been used for treating iron deficiency, as contrast agents for magnetic resonance imaging and as drug carriers. Here, we show an intrinsic therapeutic effect of ferumoxytol on the growth of early mammary cancers, and lung cancer metastases in liver and lungs. In vitro, adenocarcinoma cells co-incubated with ferumoxytol and macrophages showed increased caspase-3 activity. Macrophages exposed to ferumoxytol displayed increased mRNA associated with pro-inflammatory Th1-type responses. In vivo, ferumoxytol significantly inhibited growth of subcutaneous adenocarcinomas in mice. In addition, intravenous ferumoxytol treatment before intravenous tumour cell challenge prevented development of liver metastasis. Fluorescence-activated cell sorting (FACS) and histopathology studies showed that the observed tumour growth inhibition was accompanied by increased presence of pro-inflammatory M1 macrophages in the tumour tissues. Our results suggest that ferumoxytol could be applied ‘off label’ to protect the liver from metastatic seeds and potentiate macrophage-modulating cancer immunotherapies.